Which therapy is useful in ER-positive breast cancer?

Which therapy is useful in ER-positive breast cancer?

• A. Chemotherapy only
• B. Anti-estrogen such as Tamoxifen
• C. Radiation therapy only
• D. Surgical excision only

Answer: (B)

ER-positive breast cancers rely on estrogen signaling to grow. Anti-estrogen therapy like Tamoxifen directly blocks that pathway. Tamoxifen binds the estrogen receptor in breast tissue and acts as an antagonist, preventing estrogen from triggering the gene transcription that drives tumor cell proliferation. This targeted approach slows or stops tumor growth and reduces the risk of recurrence, which is why it is preferentially used in ER-positive disease. Local treatments such as surgical removal or radiation address the tumor in a specific area but do not interfere with the systemic hormone-driven growth. Chemotherapy works broadly and can be used in many situations, but it doesn’t exploit the tumor’s hormone receptor status as endocrine therapy does. Aromatase inhibitors are another endocrine option, especially in postmenopausal patients, reinforcing the idea that blocking estrogen signaling is central to treating ER-positive disease.

ER-positive breast cancers rely on estrogen signaling to grow. Anti-estrogen therapy like Tamoxifen directly blocks that pathway. Tamoxifen binds the estrogen receptor in breast tissue and acts as an antagonist, preventing estrogen from triggering the gene transcription that drives tumor cell proliferation. This targeted approach slows or stops tumor growth and reduces the risk of recurrence, which is why it is preferentially used in ER-positive disease.

Local treatments such as surgical removal or radiation address the tumor in a specific area but do not interfere with the systemic hormone-driven growth. Chemotherapy works broadly and can be used in many situations, but it doesn’t exploit the tumor’s hormone receptor status as endocrine therapy does. Aromatase inhibitors are another endocrine option, especially in postmenopausal patients, reinforcing the idea that blocking estrogen signaling is central to treating ER-positive disease.